A multi-center randomized comparison study of CAF + TAM therapy (Arm A) and CAF+MPA therapy (Arm B) in advanced or recurrent breast cancer was conducted at 37 institutions in Kyushu. Out of 119 registered cases, 114 were eligible and 76 were evaluable. The response rate was 42% (15/36) in Arm A and 58 % (23/40) in Arm B. In the comparison of side effects, nausea/vomiting and anorexia were significantly less and moon face and body weight gain were significantly more in Arm B. Leucocytopenia was significantly inhibited in Arm B compared with Arm A, which indicated the myeloprotective effect of MPA. These results indicated that CAF + MPA therapy (Arm B) may be more advantageous than CAF + TAM therapy (Arm A) in advanced or recurrent breast cancer.
|ジャーナル||Japanese Journal of Cancer and Chemotherapy|
|出版ステータス||出版済み - 12 1 1995|
All Science Journal Classification (ASJC) codes
- Cancer Research